TY  - JOUR
PY  - 2008//
TI  - Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study
JO  - Epilepsy research
A1  - Belcastro, Vincenzo
A1  - Costa, Cinzia
A1  - Galletti, Francesca
A1  - Autuori, Alessia
A1  - Pierguidi, Laura
A1  - Pisani, Francesco
A1  - Calabresi, Paolo
A1  - Parnetti, Lucilla
SP  - 223
EP  - 226
VL  - 82
IS  - 2-3
N2  - Levetiracetam (LEV) monotherapy was investigated in 35 patients (pts) (16M/19F, 71.9+/-7.3 years of age) with late-onset post-stroke seizures (i.e. seizures occurring at least 2 weeks after an ischemic stroke) in a prospective open-label study. Overall, 27 pts (77.1%) achieved a condition of seizure freedom (defined as 1 year without seizures): 19 (54.3%) at a daily LEV dose of 1000mg, 7 (20.0%) at 1500mg, 1 (2.8%) at 2000mg. Four pts (11.4%) discontinued the drug because of intolerable side effects (drowsiness associated to gait disturbance in 1 pt, and aggressive behaviour in the remaining 3 pts); 3 pts were unresponsive at a dose of 3000mg, and 1 pt was lost at follow-up. These observations suggest that LEV exhibits safety and efficacy profiles which make it an optimal candidate as a first-choice drug against post-stroke seizures.<p /> <p>Language: en</p>
LA  - en
SN  - 0920-1211
UR  - http://dx.doi.org/10.1016/j.eplepsyres.2008.08.008
ID  - ref1
ER  -